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NXY-059 for Acute Ischemic Stroke
The Promise of Neuroprotection Is Finally Realized?
Marc Fisher, MD
The SAINT I article reports the results of a phase III trialof the free-radical-spin trap, neuroprotective agent, NXY-
059 in acute ischemic stroke. The study had a statistically
significant effect on the primary outcome measure, the range
of 90-day outcomes on the modified Rankin Scale (mRS), a
measure of functional outcome after stroke. The change in
National Institutes of Health Stroke Scale (NIHSS) scores
from baseline, the principal secondary outcome variable, was
not effected by treatment with NXY-059. The primary
outcome measure used in this trial is novel and has not to my
knowledge been used in prior acute stroke trials. The obser-
vation in a post hoc analysis of a significant reduction of
symptomatic and asymptomatic hemorrhage with NXY-059
in patients who were treated with IV tissue plasminogen
activator (t-PA) is also encouraging. It suggests that NXY-
059 could be a useful adjunct in stroke patients treated with
IV recombinant t-PA to reduce hemorrhagic risk, if
reproduced.
The primary outcome measure of a shift in the mRS in a
favorable direction achieved statistical significance, and this
observation substantiates the importance of this clinical trial. It is
the first neuroprotective trial in acute ischemic stroke to achieve
a significant treatment effect on its primary outcome measure.1
Using a shift of the mRS across the entire spectrum of mRS
scores is an important innovation. In prior acute stroke therapy
trials, the mRS was typically dichotomized and occasionally
trichotomized. When the mRS is dichotomized with a cut point
at 1 or 2 and the primary end point is a comparison of the
percentage of patients achieving an mRS of 0 to 1 or 0 to 2 in the
active treatment group versus placebo, the trial is essentially
looking for “cures”. The mRS shift approach is designed to look
for a broadly defined treatment effect and not only patients with
little or no deficit.2 Certainly for neuroprotective drugs and likely
also for thrombolytics, this mRS shift assessment across the
entire range of the scale is more appropriate than looking for a
“cure”. In animal studies of both types of therapies, a treatment
is considered successful if infarct size is reduced by a reasonable
percentage and the goal is not to reduce infarct size to a small
percentage of the involved hemisphere or zero.3
The authors report that the number-needed-to-treat to
improve by 1 point on the mRS is 7.8. This is the best-case
scenario. In fact, the most likely scenario is that some
percentage of patients improved by 2 points and perhaps a
few by 3 or 4 points. The number-needed-to-treat for mRS
improvement in this study was likely somewhere between 9
to 12 between the estimate of 7.8 for a 1-point improvement
and 15.5 for a 2-point improvement. If the approach of
improving by 1 point on the mRS is used, the authors state
that this “represents a clinically meaningful shift”. This
statement is clearly true for a shift from 4 to 3 or 3 to 2, but
a shift from 2 to 1 or even 1 to 0 is less obviously clinically
meaningful. The mRS is burdened to some degree by seman-
tics and subtlety.4 The impact on patients of being classified
0 versus 1 or 1 versus 2 is not always obvious to patients, care
givers or physicians.
The observation that NXY-059 significantly reduced the
rate of symptomatic and asymptomatic hemorrhages associ-
ated with IV t-PA use within the approved 3-hour window is
intriguing. It suggests that this spin-trap agent may indeed be
protective regarding t-PA–related hemorrhagic transforma-
tion of ischemic stroke, potentially by reducing endothelial
cell injury. If this observation is confirmed in the larger
SAINT II trial, then combination therapy will likely become
standard when t-PA is used for acute ischemic stroke. Future
studies with later initiation of t-PA therapy beyond the
current 3-hour window could then be performed with NXY-
059 to determine whether pretreatment with the neuropro-
tectant has even greater effects on hemorrhagic transforma-
tion and possibly extends the time window for the successful
use of IV t-PA. The observation of a reduced rate of
hemorrhage with NXY-059 in combination with IV t-PA
does raise the question of how much of the overall benefit
observed in the SAINT I trial is related to a reduced number
of hemorrhages associated with t-PA use. Although most of
the hemorrhagic reduction was termed asymptomatic, be-
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cause a 4-point or greater decline in the NIHSS score was not
seen within 36 hours, it is possible that more subtle early
clinical declines could be associated with effects on the
day-90 mRS outcome. Unfortunately, the article does not
address directly the treatment effect ascribable to this reduc-
tion of t-PA–related hemorrhagic transformation.
The SAINT I trial is an important and timely step forward
for the arena of acute stroke therapy development. The trial
incorporated many lessons learned from prior unsuccessful
neuroprotection trials and also innovated the use of a reason-
able, clinically meaningful end point to evaluate therapeutic
response. Hopefully, the results of the ongoing SAINT II trial
will corroborate the results of SAINT I and lead to regulatory
approval. This modest but clinically meaningful advance
should then serve as a springboard for many future trials to
enhance acute stroke therapy that will lead to maximizing
clinical benefits.
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